| dc.contributor.author | Esther Forkosh | |
| dc.contributor.author | Yaron Ilan | |
| dc.contributor.other | Medicine, Hebrew University Hadassah Medical Center, Jerusalem, Israel | |
| dc.contributor.other | Medicine, Hebrew University Hadassah Medical Center, Jerusalem, Israel | |
| dc.date.accessioned | 2025-10-09T05:16:18Z | |
| dc.date.available | 2025-10-09T05:16:18Z | |
| dc.date.issued | 01-May-2019 | |
| dc.identifier.uri | https://openheart.bmj.com/content/6/1/e000993.full | |
| dc.identifier.uri | http://digilib.fisipol.ugm.ac.id/repo/handle/15717717/40900 | |
| dc.description.abstract | The human gut microbiota has been identified as a possible novel risk factor for cardiovascular disease. The intestinal microbiome plays a role in the pathogenesis of atherosclerosis and heart failure. Even though studies in rodents suggested that gut microbes may affect the risk of heart disease, this link has not been shown in humans. In the present study, we review several potential mechanisms by which the gut microbiome and bacterial translocation are associated with the development of cardiac disorders making them potential targets for novel therapeutic measures for these conditions. Modulation of the gut microbiota as a mechanism for altering the pathogenesis of disorders is an area of growing interest. Alteration in the gut microbiota is being explored as a method of reducing risk factors associated with cardiac diseases. | |
| dc.language.iso | EN | |
| dc.publisher | BMJ Publishing Group | |
| dc.subject.lcc | Diseases of the circulatory (Cardiovascular) system | |
| dc.title | The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy | |
| dc.type | Article | |
| dc.description.doi | 10.1136/openhrt-2018-000993 | |
| dc.title.journal | Open Heart | |
| dc.identifier.e-issn | 2053-3624 | |
| dc.identifier.oai | oai:doaj.org/journal:c4488802439044709098a3b29e79a9f3 | |
| dc.journal.info | Volume 6, Issue 1 | |
